AMA CPT® Assistant - 2021 Issue 5 (May)
New COVID-19 Vaccine Codes (May 2021 Special Edition)
Current Procedural Terminology (CPT®) codes for a new vaccine product from Novavax and its administration have been added to previously established vaccine codes for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease 2019 [COVID-19]). The CPT Editorial Panel has approved the latest vaccine product code, which will become effective upon receiving the Emergency Use Authorization (EUA) or approval from the Food and Drug Administration (FDA). In order to assist CPT code users in differentiating and appropriately reporting the available vaccine product codes and their affiliated immunization administration codes, the American Medical Association (AMA) established a website (https:// www...
Subscribe or sign in to view the full article.
Article Overview
This CPT Assistant special edition explains recent COVID-19 vaccine coding updates related to a new Novavax product, its administration coding, and supporting reference materials. It is relevant to coders, billers, compliance staff, and clinical documentation teams who track vaccine code changes and CPT guidance. The article also references prior COVID-19 vaccine coding updates, AMA resources, and the organization of vaccine information in CPT Appendix Q.
Why This Topic Matters
COVID-19 vaccine coding changed quickly during the public health emergency, and this update helps readers understand how newly established vaccine and administration codes fit into the CPT system. It matters for accurate reporting, code maintenance, and staying aligned with current AMA/CPT guidance.
Article Sections
-
COVID-19 vaccine coding update overview
Introduces the latest CPT vaccine coding changes and the context for the update. It frames the article around newly added product and administration codes and related reference resources.
-
Immunization Administration for Vaccines/Toxoids
Summarizes the immunization administration code area relevant to vaccine reporting. This section groups general administration guidance alongside the COVID-19-related administration codes discussed in the article.
-
Vaccines, Toxoids
Presents the vaccine product code discussion and its placement within the CPT vaccine code category. It also links the product information to associated administration references.
-
Clinical Example (91304) / Description of Procedure (91304)
Provides an illustrative scenario and corresponding procedural narrative for the vaccine product entry. The section is included as paired example-and-procedure material for the cited code.
-
Clinical Example (0041A) / Description of Procedure (0041A)
Provides an illustrative scenario and corresponding procedural narrative for the first administration code. It reflects the article’s example-based guidance for reporting the related COVID-19 vaccine administration.
-
Clinical Example (0042A) / Description of Procedure (0042A)
Provides an illustrative scenario and corresponding procedural narrative for the second administration code. It reflects the article’s example-based guidance for reporting the related COVID-19 vaccine administration.
-
Reference
Lists a source citation used to support the vaccine update discussion. This section contains background reference material rather than coding guidance.
What You Will Learn
- How the article frames recent COVID-19 vaccine coding updates in CPT
- What kinds of vaccine product and administration topics are covered
- How CPT Appendix Q is described in relation to vaccine reference information
- What supporting examples and procedural narratives are included for the new vaccine coding content
Who Should Read This
- Medical coders
- Medical billers
- Compliance professionals
- Revenue cycle staff
- Clinical documentation specialists
- Immunization program staff
Codes Discussed
Code Ranges Discussed
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com
